Cynata Therapeutics (ASX: CYP) has executed a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead product, CYP-001. CYP-001 is an induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSC) product that is anticipated to be the first allogeneic iPSC product to enter a clinical trial.
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Mesoblast Securing IP Portfolio for Use of Mesenchymal Precursor Cells
Mesoblast has been granted a key patent by the United States Patent and Trademark Office (USPTO) for use of its Mesenchymal Precursor Cells (MPCs) in the treatment of rheumatic diseases, including rheumatoid arthritis (RA). Mesoblast is global company that specializes in developing cell-based therapies that utilize mesenchymal precursor cells (MPCs) and mesenchymal stem cells (MSCs).
The Company’s patent portfolio in the United States for the treatment of RA and related conditions “comprises the newly and recently granted patents, US 9,381,216 and US 9,265,796, which cover treatment of rheumatic diseases by administration of STRO-1 positive MPCs.”
According to Dr. Allan Gibofsky, Professor at Weill Cornell Medical College, “The trial used standardized parameters consistent with United States Food and Drug Administration (FDA) guidance for RA product development. Importantly, there was consistency observed in the dose-related responses for clinical symptoms, physical function and disease activity parameters at 12 weeks in line with the trial’s pre-specified efficacy endpoints.”
To learn more, view the Mesoblast press announcement.
Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare
Bioquark Inc. and RegenerAge SAPI de CV will focus on translational therapeutic applications of a range of regenerative and rejuvenation based healthcare interventions, with the goal of reducing human degeneration, suffering, and death.
Philadelphia, PA, USA/ Mexico City, Mexico; JULY 19, 2016 – Bioquark, Inc., a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenative healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.
“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.” [Read more…]
Landmark Stem Cell Clinical Trial Testing Escalating Doses of AST-OPC1 (Oligodendrocyte Progenitors)
Below is a press release from Santa Clara Valley Medical Center (SCVMC), a site in the AST-OPC1 SCiSTAR Phase 1/2a clinical trial in complete cervical spinal cord injury, which is being sponsored by BioTime, Inc. (NYSE MKT: BTX) subsidiary Asterias Biotherapeutics (NYSE MKT: AST).
The clinical trial will test the safety of three varying doses of AST-OPC1, which are oligodendrocyte progenitors that have the capacity to differentiate into a variety of brain cells. The California Institute of Regenerative Medicine (CIRM) also released a blog post about the procedure conducted at SCVMC.
The SCiSTAR study being run by Asterias Biotherapeutics is funded in part by a $14.3 million grant from CIRM. [Read more…]
Axol Bioscience to Launch Novel iPSC-Derived Cells at ISSCR 2016
The human cell culture specialists showcase innovative tools and applications for disease modelling and drug discovery
Cambridge, UK, 1 June 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three exciting products at International Society for Stem Cell Research (ISSCR) 2016 taking place in San Francisco, CA from 22 – 25 June. This includes: Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery plc. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes. [Read more…]